Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report

Yubao Wang, Kermit V Speeg, William Kenneth Washburn, Glenn A Halff

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.

Original languageEnglish (US)
Pages (from-to)5518-5522
Number of pages5
JournalWorld Journal of Gastroenterology
Volume16
Issue number43
DOIs
StatePublished - Nov 21 2010

Fingerprint

Sirolimus
Liver Transplantation
Hepatocellular Carcinoma
Recurrence
Fetal Proteins
Immunosuppression
Disease Progression
Therapeutics
Tomography
Transplants
Lung
Serum
sorafenib

Keywords

  • Hepatocellular carcinoma
  • Liver transplantation
  • Mammalian target of rapamycin inhibitor
  • Sirolimus
  • Sorafenib

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation : A case report. / Wang, Yubao; Speeg, Kermit V; Washburn, William Kenneth; Halff, Glenn A.

In: World Journal of Gastroenterology, Vol. 16, No. 43, 21.11.2010, p. 5518-5522.

Research output: Contribution to journalArticle

@article{7926cf82dc8448e6809a65a951ede2b4,
title = "Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report",
abstract = "A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.",
keywords = "Hepatocellular carcinoma, Liver transplantation, Mammalian target of rapamycin inhibitor, Sirolimus, Sorafenib",
author = "Yubao Wang and Speeg, {Kermit V} and Washburn, {William Kenneth} and Halff, {Glenn A}",
year = "2010",
month = "11",
day = "21",
doi = "10.3748/wjg.v16.i43.5518",
language = "English (US)",
volume = "16",
pages = "5518--5522",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "43",

}

TY - JOUR

T1 - Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation

T2 - A case report

AU - Wang, Yubao

AU - Speeg, Kermit V

AU - Washburn, William Kenneth

AU - Halff, Glenn A

PY - 2010/11/21

Y1 - 2010/11/21

N2 - A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.

AB - A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.

KW - Hepatocellular carcinoma

KW - Liver transplantation

KW - Mammalian target of rapamycin inhibitor

KW - Sirolimus

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=78649687544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649687544&partnerID=8YFLogxK

U2 - 10.3748/wjg.v16.i43.5518

DO - 10.3748/wjg.v16.i43.5518

M3 - Article

C2 - 21086573

AN - SCOPUS:78649687544

VL - 16

SP - 5518

EP - 5522

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 43

ER -